Last updated 2026-07-26
- Raised $45M Series C led by NFDOS, Jan 2020
- Raised $8.8M Series B led by Starr Ventures, Nov 2017
- Raised $9.2M Series A led by Starr Ventures, Sep 2016
Total raised
$63.0M
Last: Undisclosed Round 2020-02
Stage
Series C
Founded
2015
Headcount
13
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
NeoTX is a clinical-stage biotechnology company leveraging its proprietary Selective T cell Redirection (STR) platform to develop targeted anticancer immunotherapies. The STR platform, also referred to as Tumor Targeted Superantigen (TTS) technology, binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating immune cells away from the suppressive tumor environment to mount an effective antibacterial response. The company's lead STR molecule, naptumomab estafenatox (NAP), is currently in clinical development for advanced solid tumors.
Funding history · 3 rounds · $63.0M total
2020-01
C Round
$45.0M
★ NFDOS★ Tako Ventures★ J. Tomilson Hil★ Maurice Greenberg
2017-11
B Round
$8.8M
★ Starr Ventures
2016-09
A Round
$9.2M
★ Starr Ventures
Headcount over time
From 8 (2018-11) to 14 (2025-12) · +6 (+75%) · 30 points · source: Finder history + radar grounding
Q&A
- What is NeoTX's primary focus?
- NeoTX is a clinical-stage biotechnology company developing targeted anticancer immunotherapies using its proprietary Selective T cell Redirection (STR) platform.
- What is the status of NeoTX's lead molecule, naptumomab estafenatox (NAP)?
- NeoTX's lead STR molecule, naptumomab estafenatox (NAP), is currently in clinical development for advanced solid tumors.
- What was NeoTX's most recent funding round?
- NeoTX completed a C Round in February 2020, raising $45,000,000. Key investors included Tako Ventures Investments and NDFOS Co.
- What is NeoTX's total funding raised to date?
- NeoTX has raised a total of $101,000,000 across its funding rounds.
- Did NeoTX make any acquisitions recently?
- In May 2022, NeoTX acquired InterX to enhance its discovery capabilities.
- Has NeoTX completed any clinical trial stages recently?
- In June 2022, NeoTX announced the successful first stage completion of its Phase 2a clinical trial of naptumomab estafenatox (NAP) in combination with docetaxel for advanced non-small cell lung cancer (NSCLC).
- Has there been any recent leadership changes at NeoTX?
- In January 2022, NeoTX Therapeutics promoted Marcel Rozencweig, M.D., to President and welcomed Scott Z. Fields, M.D., as the new Chief Medical Officer.
Team · 5
Asher Nathan
Founder · CEO
Ramona Lloyd
Founder · VP Regulatory
Marcel Rozencweig
Founder · President, Former Chief Medical Officer
Roger Kornberg
Founder · Chairman of the Board, Former Chief Scientist
Robert Harow
Founder · Chief Financial Officer, Chief Operating Officer
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
drug-developmentdrug-discoverybiopharmaceuticalcancer-therapyoncologycancertherapeuticsimmunotherapycell-therapypharmaceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | neotx.com/ |
|---|---|
| linkedin.com/company/27245756 | |
| Wikipedia | he.wikipedia.org/wiki/%D7%A0%D7%90%D7%95%D7%98%D7%A7%D7%A1 |
| Wikidata | wikidata.org/wiki/Q137781710 |
Identifiers & details
| Legal name | NeoTX Therapeutics, Ltd. |
|---|---|
| Founded | 2015 |
| Employees (exact) | 13 |
| Wikidata QID | Q137781710 |
Radar intelligence
Patents
| EPO | 5 |
|---|
Publications (Crossref)
| Works | 9 |
|---|
Web history (Wayback)
| Domain | neotx.com |
|---|
Wikidata
| QID | Q137781710 |
|---|
Certificate / subdomain footprint
| Subdomains | 21 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515220929 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2015-04-13 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | פקריס 2 רחובות |